Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News on Pharma

1 Resilient Growth Stock to Buy Now and Hold Forever

Biopharmaceutical giant Gilead Sciences’ (GILD) shares have risen nearly 30% over the past year despite lingering macroeconomic challenges. Moreover, the company delivered solid growth last year and is expected to maintain its business momentum in 2023 and beyond, driven by its diversified medicines portfolio. Hence, investors could consider buying and…

StockNews.com

3 Biotech Stocks With Potential to Be Big Winners in 2023

The biotech industry is well-positioned to grow strongly, given the ever-rising demand for therapies and favorable government initiatives. Looking at the industry’s long-term prospects, fundamentally strong biotech stocks Amgen (AMGN), Biogen (BIIB), and Jazz Pharmaceuticals (JAZZ) could emerge as big winners this year. Keep reading….

StockNews.com

Uzbekistan cough syrup deaths case: 3 employees of Noida pharma firm arrested

NOIDA: Three employees of a Noida-based pharmaceutical firm Marion Biotech, whose cough syrup is alleged to have led to the death of 18 children in Uzbekistan last year, were arrested on charges of manufacturing and sale of adulterated drugs, officials said.

The Times of India

From analysis to the latest developments in health,
read the most diverse news in one place.

3 Best Stocks to Own for Passive Income in 2023

The Fed is expected to keep hiking rates to achieve its target inflation rate. Amid rising volatility, investor sentiment toward dividend investing has been improving. Here are three quality dividend-paying stocks, Novartis (NVS), Bristol-Myers Squibb (BMY), and Canon (CAJ), which will ensure a steady passive income stream in 2023. Keep…

StockNews.com

FDA has new leverage over companies looking for a quicker drug approval

The Food and Drug Administration has new tools to hold drug companies accountable for promises they make about medications. But the agency has yet to show its hand in using this new power.

WEKU

‘Hero’ journalist congratulated after Eli Lilly lowers price of insulin after his spoof tweet raised awareness

Eli Lilly’s CEO challenged other pharmaceutical companies to drop insulin prices as well

The Independent UK

Victoria tips $10m into mRNA vaccine workforce training

Victoria is pouring $10 million into training Australia's vaccine workforce, ahead of the southern hemisphere's first mRNA production site opening in 2024.

The New Daily

Read news from The Economist, FT, and more,
with one subscription

Rarecan eyes up to £3m investment this year as cancer platform targets rapidly growing market

The Hexham-based start-up is on the hunt for a lead investor to take it into its next funding round

Birmingham Post

Pfizer’s RSV vaccine wins US panel’s backing for safety in older people

WASHINGTON — Pfizer Inc.’s vaccine for respiratory syncytial virus received endorsement from a key panel of U.S. advisers for its safety in people 60 and older, a key endorsement for the drugmaker’s potential product.

Tribune News Service

Croda's sales top £2b as profits hit £500m for East Yorkshire smart science giant

Powerful operating model and consistent execution hailed as record performance revealed

Birmingham Post

After capping insulin copays, Colorado sets its sights on EpiPens

Almost four years after becoming the first state to cap insulin copayments, Colorado may limit what consumers pay for epinephrine autoinjectors, also known as EpiPens, which treat serious allergic reactions.

Tribune News Service

1 Dividend Stock to Buy for Passive Income in 2023

Healthcare giant Johnson & Johnson (JNJ) has a six-decade-long history of consecutive dividend growth. So, given the uncertainties surrounding the market, this fundamentally strong dividend-paying stock might be an ideal buy now. Read more.

StockNews.com

Glasgow university spin-out secures £8.75 million for tennis elbow treatment trials

The business will use the new funds to advance development of its microRNA therapeutics

Insider UK

Queensland government announces pill testing trial at fixed and mobile sites

The government announces it is developing protocols around how the testing will operate, and is searching for a provider to trial at fixed and mobile locations in the state.

ABC News

Get all your
news in one place.

100's of premium titles.
One news app.

Birmingham Post

Bristol pharmacy tech firm grows workforce amid ‘deluge’ of demand

Titan PMR has developed a cloud-based software that helps pharmacies to manage medicine dispensing and control of business activities

StockNews.com

1 Pharma Stock Poised for a Promising 2023

Following a year of solid growth in 2022, leading pharma company AstraZeneca’s (AZN) robust pipeline and recent launches look promising. Moreover, its strong fundamentals should enable the stock to deliver solid returns this year. So, AZN could be an ideal buy. Keep reading.

Tribune News Service

FDA expands contaminated eye product warning due to potential bacterial contamination, risk of blindness

The Food and Drug Administration is adding to a list of eye-care products consumers should stop using “immediately” over concerns of possible bacterial contamination that could lead to blindness if infection occurs.

Tribune News Service

Family of Henrietta Lacks asks court to reject Thermo Fisher’s second motion to dismiss lawsuit

BALTIMORE — Family members of Henrietta Lacks are asking a federal judge to reject Thermo Fisher Scientific’s second attempt to get the court to dismiss the family’s lawsuit against the multimillion-dollar biotech company.

Get all your
news in one place.

100's of premium titles.
One news app.

StockNews.com

3 Biotech Stocks to Buy and Hold for the Next 20 Years

The biotech industry is well-positioned for long-term growth owing to strong demand and continued breakthroughs. Furthermore, favorable government funding should boost the industry’s growth. Hence, it could be wise to buy and hold fundamentally sound biotech stocks Amgen (AMGN), Biogen (BIIB), and Amicus Therapeutics (FOLD) for the next two decades.…

Daily Mirror

Fears of new 'zombie drug' which rots users' skin and could even lead to amputations

Animal sedative xylazine started being used on the streets of Puerto Rico but has recently been found in major cities in the US, and causes people's skin to rot off, requiring amputations

StockNews.com

Is Bristol-Myers a Good Dividend Stock to Pick up Right Now?

Leading pharma company Bristol-Myers Squibb’s (BMY) fiscal year 2022 revenue and EPS were in line with analysts’ estimates. While BMY continues to advance its innovative portfolio and pipeline, is it a good dividend stock to pick up right now? Read more to find out.

Wales Online

Lateral flow test to detect pregnancy to go on sale in the UK

The SaliStick test kit is thought to be the first of its type in the world

Daily Mirror

World's first saliva test to tell if you're pregnant is coming to the UK

The SaliStick test kit was developed by Israeli start-up Salignostics and promises to deliver results in 10 minutes - and is similar to a lateral flow test for coronavirus

StockNews.com

1 Medical Stock to Buy in February and 1 to Avoid Like the Plague

The medical industry is expected to grow due to increasing healthcare requirements and federal support. Moreover, given the inelastic demand for healthcare products and services, fundamentally strong medical stock Nature's Sunshine Products (NATR) could be an ideal buy this month. However, SNDL (SNDL) might be best avoided, considering its weak…

StockNews.com

4 Pharma Stocks to Buy Now for the Long Haul

The pharma industry has experienced tremendous growth in recent years. The industry should continue to grow, driven by the growing market for personalized medicine and e-pharmacies. Hence, pharma stocks Pfizer (PFE), AstraZeneca (AZN), Bristol-Myers Squibb (BMY), and Zoetis (ZTS) might be worth buying for the long term. Also, these companies…

1 … 59 60 61 62

People

Mangeet Kaur BounsMangeet

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.